Midomafetamine not checked
Resilient Pharmaceuticals · 3 · 4-methylenedioxymethamphetamine
FollowEvery change as it happens, and a Monday email
Trials
5 active
26 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Midomafetamine HCl is administered orally to study participants.”In the company’s words, NCT07584720 on ClinicalTrials.gov
- Tested for
- Pharmacokinetics, Hepatic Impairment
- Main trialPhase 1
- “This Phase 1 study is designed to evaluate the safety and tolerability of midomafetamine in healthy adult participants. The study will also assess how the drug is processed in the body and characterize its effects following administration at two dose levels, including evaluation of cardiac safety using electrocardiographic assessments. This is a single-center, open-label study in which participants will be enrolled into one of two cohorts receiving either a therapeutic dose or a supratherapeutic dose of midomafetamine. Participants will receive study drug in a split dose administration (an…”In the company’s words, NCT07584720 on ClinicalTrials.gov
- Other names
- 3 · 4-methylenedioxymethamphetamine · MDMA · MDMA HCl
Other drugs for Hepatic Impairment
- Custodiol-NDr. F. Köhler Chemie GmbH · Phase 3
- Rifaximin SSDBausch Health Americas, Inc. · Phase 3
- TYNADOTESinew Pharma Inc. · Phase 2
- LYG-LIV0001LyGenesis, Inc. · Phase 2
- NTZGenfit · Phase 2
- EGEN-5784eGenesis, INC · Phase 1/2
Coming up1
- Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials26
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 23 Jul 2026 | Study of Midomafetamine in Healthy Adults | |
| Phase 1Not yet recruiting | Dec 2028 | MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function | |
| Phase 3Completed | 11 Aug 2020 | A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) | |
| Phase 3Completed | 30 Oct 2022 | A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) | |
| Phase 3Completed | 1 Nov 2023 | A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD | |
| Phase 2Completed | 2 May 2008 | MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder | |
| Phase 2Terminated | Mar 2009 | Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel | |
| Phase 2Completed | 27 Jun 2014 | Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial | |
| Phase 2Terminated | 10 Sep 2015 | Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD | |
| Phase 2Completed | 3 Dec 2015 | Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD | |
| Phase 2Completed | 25 Apr 2017 | MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness | |
| Phase 2Completed | 28 Apr 2017 | Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults | |
| Phase 2Completed | 4 Jun 2019 | Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada) | |
| Phase 2Completed | 10 Aug 2019 | Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD | |
| Phase 2Withdrawn | Aug 2023 | Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD | |
| Phase 2Terminated | 25 Jun 2024 | Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD | |
| Phase 2Withdrawn | Dec 2024 | Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans | |
| Phase 2Withdrawn | 10 Aug 2028 | A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders | |
| Phase 1/2Completed | 16 Dec 2017 | MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD | |
| Phase 1Completed | 1 Aug 2020 | Evaluation of MDMA on Startle Response | |
| Phase 1Completed | 5 Aug 2022 | Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers | |
| Phase 1Completed | 2 Dec 2022 | Food Effects on Bioavailability of MDMA in Healthy Volunteers | |
| Phase 1Withdrawn | Dec 2025 | Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2) | |
| Phase 2Authorised | not given | High-Intensity Inpatient MDMA-Assisted Psychotherapy for Treatment-Refractory Posttraumatic Stress Disorder: An Open-Label Pilot Study | |
| Phase 2Authorised | not given | MDMA-assisted therapy for adolescents with treatment-resistant PTSD | |
| Phase 2Authorised | not given | A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026